Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion PORTERI, Corinna, FRISONI, Giovanni New criteria for the diagnosis of Alzheimer's disease (AD) based on biomarker results have recently been developed and are currently undergoing extensive validation. The next few years may represent a time window where the diagnostic validity of biomarkers will be studied in highly specialized research settings. Biomarkers results will be used to direct clinical diagnosis and, whenever appropriate, therapy and management. This piece aims to stimulate discussion by identifying the ethical challenges involved in the use of biomarkers to make a diagnosis of m...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
International audienceIn 2018, the US National Institute on Aging and the Alzheimer's Association pr...
BACKGROUND: Today, many healthcare or dementia organizations, clinicians, and companies emphasize th...
New criteria for the diagnosis of Alzheimer's disease (AD) based on biomarker results have recently ...
New criteria for the diagnosis of Alzheimer’s disease (AD) based on biomarker results have recently ...
doi: 10.3389/fnagi.2014.00041 Biomarker-based diagnosis of mild cognitive impairment due to Alzheime...
There is great interest in the use of biomarkers to assist in the timely identification of Alzheimer...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of aging that presents with mem...
Abstract: More and more frequently, clinical trials for Alzheimer disease (AD) are targeting cogniti...
Background: The NIA-AA research framework proposes a purely biological definition of Alzheimer’s dis...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Item does not contain fulltextBACKGROUND: The shift to defining Alzheimer's disease (AD) as a biolog...
Today, more than 46 million people worldwide are living with dementia (Wimo et al., 2013). This numb...
Abstract: An increasing number of people seek medical attention for mild cognitive symptoms at older...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
International audienceIn 2018, the US National Institute on Aging and the Alzheimer's Association pr...
BACKGROUND: Today, many healthcare or dementia organizations, clinicians, and companies emphasize th...
New criteria for the diagnosis of Alzheimer's disease (AD) based on biomarker results have recently ...
New criteria for the diagnosis of Alzheimer’s disease (AD) based on biomarker results have recently ...
doi: 10.3389/fnagi.2014.00041 Biomarker-based diagnosis of mild cognitive impairment due to Alzheime...
There is great interest in the use of biomarkers to assist in the timely identification of Alzheimer...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of aging that presents with mem...
Abstract: More and more frequently, clinical trials for Alzheimer disease (AD) are targeting cogniti...
Background: The NIA-AA research framework proposes a purely biological definition of Alzheimer’s dis...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Item does not contain fulltextBACKGROUND: The shift to defining Alzheimer's disease (AD) as a biolog...
Today, more than 46 million people worldwide are living with dementia (Wimo et al., 2013). This numb...
Abstract: An increasing number of people seek medical attention for mild cognitive symptoms at older...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
This article presents recommendations, based on the Grading of Recommendations, Assessment, Developm...
International audienceIn 2018, the US National Institute on Aging and the Alzheimer's Association pr...